Personalized treatment for prostate cancer to improve quality of life after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to personalize treatment for prostate cancer patients who have detectable PSA levels after prostatectomy. It compares the effects of apalutamide-based therapy versus standard androgen deprivation therapy (ADT) on fatigue and quality of life in two cohorts: those with less aggressive disease and those with more aggressive disease. The study will assess various outcomes, including patient-reported quality of life, toxicity, activity levels, cognitive function, and metabolic changes over time. Participants will be monitored for 9 to 24 months depending on their risk category.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically confirmed prostate cancer.
2. PSA ≥ 0.1 after radical prostatectomy.
3. Candidate for salvage radiation and ADT treatment, as determined by treating physician.
4. Age \>18 at the time of consent.
5. ECOG Performance Status ≤ 2.
6. Demonstrate adequate organ function as defined in the table below. All screening labs to be obtained within 90 days of registration.

   System Laboratory Value

   Hematological:

   Platelet count (plt) = ≥ 100,000/µL

   Hemoglobin (Hgb) = ≥ 9 g/dL

   Renal:

   eGFR = ≥ 30 mL/min using MDRD Formula

   Hepatic and Other:

   Bilirubin2 = ≤1.5 x upper limit of normal (ULN) Aspartate aminotransferase (AST) = ≤ 2.5 x ULN Alanine aminotransferase (ALT) = ≤ 2.5 x ULN Serum Albumin = \> 3.0 g/dL Serum potassium = ≥ 3.5 mmol/L 2In subjects with Gilbert's syndrome, if total bilirubin is \>1.5 x ULN, measure direct and indirect bilirubin; if direct bilirubin is ≤ 1.5 x ULN, subject may be eligible.
7. Ability to understand and comply with study procedures for the entire length of the study as determined by the site investigator or protocol designee.
8. Ability to understand English or Spanish language as determined by the site investigator or protocol designee. Since the primary outcome is a questionnaire available in English and Spanish.
9. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. Participants must have the ability to understand and willingness to sign the written informed consent document.

Exclusion Criteria:

1. Use of post-prostatectomy testosterone suppression prior to registration (use of GnRH agonist or antagonist, with or without an anti-androgen). However, participants with testosterone recovery after post-prostatectomy testosterone suppression are eligible (testosterone recovery defined as total testosterone \> 190 ng/dL) regardless of how long their testosterone was suppressed.
2. Use of testosterone suppression prior to prostatectomy if the ArteraAI Prostate Test (Post-RP) is required to risk stratify patients (those patients with PSA ≤0.5 and no evidence of nodal involvement require ArteraAI Prostate Test (Post-RP) to stratify).
3. Confirmed extrapelvic or bone disease based on conventional imaging
4. History of any of the following:

   * Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1 year prior to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy).
   * Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization. Any condition that in the opinion of the investigator, would preclude participation in this study.
5. Current evidence of any of the following:

   * Uncontrolled hypertension (consistently \>160 systolic or \>100 diastolic)
   * Gastrointestinal disorder affecting absorption
   * Active infection (eg, human immunodeficiency virus \[HIV\] or viral hepatitis).
   * Any condition that in the opinion of the investigator, would preclude participation in this study.
6. Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

8\) Medications known to lower the seizure threshold (listed in section 5 below) must be discontinued or substituted 4 weeks prior to C1D1 of study treatment for participants on arms receiving apalutamide.

Where it's running

• Banner MD Anderson
  Gilbert, Arizona, United States Recruiting
• Rush MD Anderson
  Chicago, Illinois, United States Recruiting
• University of Kansas Medical Center
  Kansas City, Kansas, United States Recruiting
• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting
• MD Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Karen Hoffman, MD — M.D. Anderson Cancer Center
• Study coordinator: Karen Hoffman, MD
• Email: khoffman1@mdanderson.org
• Phone: (713) 563-2339

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nerve-Sparing Robotic Prostatectomy: How Baseline Health Affects Post-Surgery Erections

  Researchers will test whether a patient’s age, health history, and pre-surgery sexual function can predict erectile function after nerve-sparing robot-assisted prostatectomy.

  Recruiting University of Florence · Florence, Italy · NCT07747272

• High Dose Rate Brachytherapy for Prostate Cancer Recurrence

  This study is testing if a special type of radiation treatment called High Dose Rate Brachytherapy can help men with prostate cancer that has come back after surgery feel better and have fewer side effects compared to regular radiation.

  Recruiting Clinica Universidad de Navarra, Universidad de Navarra · Pamplona, Foral Community of Navarre · NCT06982469

• Treatment for male overactive bladder using sacral neuromodulation

  This study is testing a new device to see if it can help men with overactive bladder feel better after prostate surgery or radiation therapy.

  Recruiting at 21 sites Axonics, Inc. · Birmingham, Alabama and 22 other locations · NCT06511141

• Pain management plan implementation for major open abdominal surgeries

  This trial tests an opioid-epidural pain management approach to see if it improves post-surgical pain control for adults undergoing open abdominal procedures like colectomy, hepatectomy, and nephrectomy.

  Recruiting National and Kapodistrian University of Athens · Athens, Athens · NCT07901582

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.